SVA Class Action Complaint Filed: Globally Recognized Law Firm Johnson Fistel Encourages Shareholders to Submit Losses to Sinovac Biotech Ltd. for the securities class action lawsuit against 1Globe Capital LLC and certain of its officers

SAN DIEGO, Aug. 19, 2022 (GLOBE NEWSWIRE) — Law firm specializing in shareholder rights Johnson Fistel, LLP announces that a class action lawsuit has been filed on behalf of the investors of Sinovac Biotech Ltd. VAS. The Sinovac class action seeks to represent the holders of Sinovac Biotech Ltd. VAS shares who sold their shares between April 11, 2016 and February 22, 2019 (the “Class Period”). Investors are hereby notified that they have until October 17, 2022 to apply to the court to serve as lead plaintiff in this action.

What actions can I take at this time? If you have suffered a loss and would like to learn more about the lead plaintiff role, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If emailing, please include a phone number.

To join this action, you can click or copy and paste the link below into a browser:

https://www.johnsonfistel.com/investigations/sinovac-biotech-1globe-sva

There is no cost or obligation for you.

The Sinovac class action lawsuit thus alleges that the defendants caused substantial harm to the class by causing them to lose their ability to collect at least millions of shares to which they would otherwise have been entitled under the rights agreement that Sinovac adopted. on March 28, 2016. The Sinovac Class Action further alleges that the defendants’ actions also caused damages due to their misrepresentations and omissions regarding 1Globe and Li’s true ownership of the Sinovac shares, and their efforts to take control of Sinovac, artificially suppressed the price of Sinovac’s shares.

A lead plaintiff will act on behalf of all other class members to lead the Sinovac class action. The lead plaintiff may select a law firm of their choice to litigate the class action. An investor’s ability to share in any potential future recovery from the Sinovac class action does not depend on its function as lead plaintiff. For more information on the lead applicant process, please see https://www.johnsonfistel.com/lead-plaintiff-deadlines.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivatives and securities class actions. Johnson Fistel is seeking to recover losses incurred due to violations of federal securities laws. For more information about the firm and its lawyers, visit http://www.johnsonfistel.com. Lawyer advertisement. Past results do not guarantee future results.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
Investor Relations
[email protected]

About the author